Back To: Home : Featured Technology : PCR/qPCR

CLICK HERE FOR WHAT'S NEW IN:
 

Cisbio Bioassays and IGF launch CNS drug discovery research program
January 2011
SHARING OPTIONS:

BAGNOLS-SUR-C»ZE, FranceóCisbio Bioassays recently launched the GluSense research and development program in partnership with the Functional Genomics Institute (IGF) of Montpellier, France. The project, financed by a $1.2 million grant from France's National Research Agency, will focus on the development of central nervous system (CNS) drug discovery research tools. The GluSense project involves sensors that enable real-time detection of responses from glutamate receptors, which are part of a family of G-protein coupled receptor (GPCR) targets that are related to CNS disorders such as Parkinson's disease and depression. Cisbio and IGF have also created a joint laboratory at IGF to investigate technologies that facilitate the study of interactions between biomolecules on the surface of living cells. These technologies will be applied to research projects focused on GPCRs, and following a technology transfer from the laboratory to Cisbio Bioassays, developed into products for use by pharmaceutical and biotechnology companies.


Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.